Overview

Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)

Status:
Active, not recruiting

Trial end date:
2021-08-10

Target enrollment:

Participant gender:

Summary

International multi-center open-label randomized clinical trial of efficacy, safety and pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) monotherapy compared to docetaxel as second-line therapy of patients with advanced inoperable or metastatic non-small cell lung cancer

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Biocad

Treatments:

Docetaxel